{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sebelipase+Alfa",
    "query": {
      "intervention": "Sebelipase Alfa"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T08:53:00.849Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02193867",
      "title": "Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency"
      ],
      "interventions": [
        {
          "name": "Sebelipase Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "Up to 8 Months"
      },
      "enrollment_count": 10,
      "start_date": "2014-06-06",
      "completion_date": "2018-10-30",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193867"
    },
    {
      "nct_id": "NCT01488097",
      "title": "Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholesterol Ester Storage Disease (CESD)",
        "Lysosomal Acid Lipase Deficiency",
        "LAL-Deficiency"
      ],
      "interventions": [
        {
          "name": "sebelipase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2011-12-12",
      "completion_date": "2017-06-21",
      "has_results": true,
      "last_update_posted_date": "2018-07-20",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 5,
      "location_summary": "Eureka, California • Sacramento, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Eureka",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488097"
    },
    {
      "nct_id": "NCT01757184",
      "title": "Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency"
      ],
      "interventions": [
        {
          "name": "Sebelipase Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2013-01-22",
      "completion_date": "2018-12-11",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757184"
    },
    {
      "nct_id": "NCT02926872",
      "title": "Screening for Lysosomal Acid Lipase Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency"
      ],
      "interventions": [
        {
          "name": "There is no intervention in the study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 22,
      "start_date": "2016-11",
      "completion_date": "2017-06-05",
      "has_results": false,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02926872"
    },
    {
      "nct_id": "NCT02112994",
      "title": "Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency"
      ],
      "interventions": [
        {
          "name": "Sebelipase Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Months and older"
      },
      "enrollment_count": 31,
      "start_date": "2014-06-24",
      "completion_date": "2017-12-28",
      "has_results": true,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112994"
    },
    {
      "nct_id": "NCT04532047",
      "title": "PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MPS I",
        "MPS II",
        "MPS IVA",
        "MPS VI",
        "Mps VII",
        "Gaucher Disease, Type 2",
        "Gaucher Disease, Type 3",
        "Pompe Disease Infantile-Onset",
        "Wolman Disease"
      ],
      "interventions": [
        {
          "name": "Aldurazyme (laronidase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2021-07-01",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04532047"
    },
    {
      "nct_id": "NCT01307098",
      "title": "Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cholesterol Ester Storage Disease(CESD)",
        "Lysosomal Acid Lipase Deficiency",
        "LAL-Deficiency"
      ],
      "interventions": [
        {
          "name": "Sebelipase alfa 0.35 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sebelipase alfa 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sebelipase alfa 3 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-04-25",
      "completion_date": "2012-01-06",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 3,
      "location_summary": "Stanford, California • New York, New York • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307098"
    },
    {
      "nct_id": "NCT01371825",
      "title": "Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Lysosomal Acid Lipase Deficiency",
        "Wolman Disease"
      ],
      "interventions": [
        {
          "name": "Sebelipase alfa (SBC-102)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 9,
      "start_date": "2011-05-04",
      "completion_date": "2018-01-03",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-09-07T08:53:00.849Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371825"
    }
  ]
}